Anavex Life Sciences Corp (AVXL)

[F1ash]

https://ars.els-cdn.com/content/image/1-s2.0-S2352873717300379-gr1.jpg.




Alzheimer's disease drug development pipeline: 2017



“In all, there are 105 agents in the pipeline as shown on clinicaltrials.gov, of which 25 are agents in 29 trials in phase I, 52 agents are in 68 trials in phase II, and 28 agents are in 42 trials in phase III. Across all stages, 70% are DMTs, 14% are symptomatic cognitive enhancers, 13% are symptomatic agents addressing neuropsychiatric and behavioral changes, and 2% have undisclosed MOAs.”

http://www.sciencedirect.com/science/article/pii/S2352873717300379



“A striking observation derived from these data is the long recruitment period anticipated for phase III DMTs. The anticipated recruitment period is often longer than the treatment period, and in many cases, these planned recruitment goals are not met [25,26]. Prevention trials require more time to recruit than prodromal trials (133.5 weeks and 105.4 weeks, respectively) and mild-moderate AD trials (106.9 weeks). Slow recruitment is among the greatest challenges to efficiency of AD drug development [14]. This observation underlies recent efforts in the AD drug development arena to advance new methods for patient recruitment including electronic engagement of potential participants, creation of registries of candidate subjects, and providing transportation, neighborhood vans, and insurance-based referral mechanisms to facilitate subject recruitment and shorten drug development timelines [27,28].”